TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.
Metrics to compare | 4157 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4157PeersSector | |
---|---|---|---|---|
P/E Ratio | −107.9x | −24.4x | −0.5x | |
PEG Ratio | 0.83 | 0.02 | 0.00 | |
Price/Book | 5.7x | 2.7x | 2.6x | |
Price / LTM Sales | 39.2x | 30.1x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.5% | |
Fair Value Upside | Unlock | −17.4% | 6.9% | Unlock |